$173.19
▲ +0.3% Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer
NBIX: Raising target price to $197.00
Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer
Overview
52-week range
$122
$168
100% of range
Avg surprise (last 3)
-21.0%
Avg reaction (last 2)
+0.4%
100% positive
Latest IV / EM
43%
EM ±9.8% · $175 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $1.41 | $1.28 | +10.2% | +1,662% | +0.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $2.04 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $1.06 | $0.98 | +8.2% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $0.08 | $0.43 | -81.4% | — | +0.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.63 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.42 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.82 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.95 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | AMC | $1.86 | $1.06 | +75.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $14M | — | $14M | $11M | $9M | — | $8M | $9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $193M | — | $239M | $146M | $24M | — | $184M | $145M |
| Net income | $198M | — | $210M | $108M | $8M | — | $130M | $65M |
| EPS (diluted) | $1.91 | — | $2.04 | $1.06 | $0.08 | — | $1.24 | $0.63 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M |
| Inventory | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M |
| Total current assets | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B |
| Total assets | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M |
| Total equity | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B |